The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Fu, Jinjian ^a,b,c   Ye, Xiaohua ^a,b   Chen, Cha ^d   Chen, Sidong ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c Liuzhou Municipal Maternity and Child Healthcare Hospital   (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANEMIA; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM EXAMINATION; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; ERADICATION THERAPY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LEUKOPENIA; LOOSE FECES; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; HUMANS; ODDS RATIO; OXAZOLIDINONES; PUBMED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84874629739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058240     Document Type: Article

References (82)

1. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, et al. (1998) Community- acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279: 593-598.
2. Vardakas KZ, Matthaiou DK, Falagas ME, (2009) Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 34: 1148-1158.
3. Klein E, Smith DL, Laxminarayan R, (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States,1999-2005. Emerg Infect Dis 13: 1840-1846.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, et al. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36: 53-59.
5. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR, (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 57: 7-13.
6. Kim HB, Park WB, Lee KD, Choi YJ, Park SW, et al. (2003) Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol 41: 2279-2281.
7. Bell JM, Turnidge JD, SENTRY APAC, (2002) High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother 46: 879-881.
8. Wang F, Zhu DM, Hu FP, Zhang YY, (2001) Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 7: 117-120.
9. European Antimicrobial Resistance Surveillance System (2002) EARSS annual report 2001. Available: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2001_EARSS_Annual_Report.pdf. Accessed 2013 January 12.
10. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, et al. (2003) Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 22: 406-419.
11. Lodise TP Jr, McKinnon PS, (2007) Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 27: 1001-1012.
12. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, et al. (2005) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41: 1373-1406.
13. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
14. Warren DK, Nitin A, Hill C, Fraser VJ, Kollef MH, (2004) Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 25: 99-104.
15. Centers for Disease Control and Prevention (CDC) (2002) Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51: 565-567.
16. Appelbaum PC, (2006) MRSA-the tip of the iceberg. Clin Microbiol Infect 12 (Suppl 2): 3-10.
17. Stevens DL, (2006) The role of vancomycin in the treatment paradigm. Clin Infect Dis 42 (Suppl 1): S51-57.
18. Khare M, Kready D, (2003) Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 4: 165-177.
19. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL, (1998) The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42: 3251-3255.
20. Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, et al. (2001) Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol 1: 470-476.
21. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, et al. (2001) Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45: 1843-1846.
22. French G, (2001) Linezolid. Int J Clin Pract 55: 59-63.
23. Falagas ME, Siempos II, Vardakas KZ, (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8: 53-66.
24. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, et al. (2010) Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 35: 3-12.
25. Dodds TJ, Hawke CI, (2009) Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg 79: 629-635.
26. Vardakas KZ, Mavros MN, Roussos N, Falagas ME, (2012) Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc 87: 349-363.
27. Moher D, Liberati A, Tetzlaff J, (2009) Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
28. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613.
29. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
30. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
31. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
32. Sofroniadou S, Revela I, Smirloglou D, Makriniotou I, Zerbala S, et al. (2012) Linezolid versus vancomycin antibiotic lock solution for the prevention of nontunneled catheter-related blood stream infections in hemodialysis patients: a prospective randomized study. Semin Dial 25: 344-350.
33. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, et al. (2001) Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 29: 1136-1145.
34. Sisson TL, Jungbluth GL, Hopkins NK, (1999) A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 39: 1277-1282.
35. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, et al. (2005) Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother 49: 3676-3681.
36. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, et al. (2005) Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 55: 333-340.
37. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH, (2003) Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51: 1239-1246.
38. Burkhardt O, Borner K, von der Höh N, Köppe P, Pletz MW, et al. (2002) Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 50: 707-712.
39. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK, (2001) Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 22: 91-97.
40. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK, (2001) Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol 41: 563-572.
41. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, et al. (2001) Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 21: 263-274.
42. Li JZ, Willke RJ, Rittenhouse BE, Glick HA, (2002) Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 22: 45S-54S.
43. Willke RJ, Glick HA, Li JZ, Rittenhouse BE, (2002) Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int J Technol Assess Health Care 18: 540-554.
44. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ, (2003) Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 4: 57-70.
45. Itani KM, Weigelt J, Li JZ, Duttagupta S, (2005) Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 26: 442-448.
46. McKinnon PS, Sorensen SV, Liu LZ, Itani KM, (2006) Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40: 1017-1023.
47. Patanwala AE, Erstad BL, Nix DE, (2007) Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 23: 185-193.
48. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, et al. (2003) Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 22 (9 Suppl): S158-163.
49. Jantausch BA, Deville J, Adler S, Morfin MR, Lopez P, et al. (2003) Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 22 (9 Suppl): S164-171.
50. Weigelt J, Kaafarani HM, Itani KM, Swanson RN, (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188: 760-766.
51. Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, et al. (2003) Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 22 (9 Suppl): S172-177.
52. Lipsky BA, Itani KM, Weigelt JA, Joseph W, Paap CM, et al. (2011) The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis 15: e140-146.
53. Duane TM, Weigelt JA, Puzniak LA, Huang DB, (2012) Linezolid and Vancomycin in Treatment of Lower-Extremity Complicated Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus in Patients with and without Vascular Disease. Surg Infect (Larchmt) 13: 147-153.
54. Grudinina SA, Zubkov MM, Krotova LA, Kurdiukova IuP, Kutsenko MA, et al. (2002) Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study. Antibiot Khimioter 47: 12-7 [Article in Russian].
55. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, et al. (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42: 597-607.
56. Sharpe JN, Shively EH, Polk HC, (2005) Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189: 425-428.
57. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, et al. (2008) Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 62 (Suppl 1): i17-28.
58. Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, et al. (2012) Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. J Antimicrob Chemother 67: 494-502.
59. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, et al. (2012) Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia. J Clin Microbiol 50: 3694-3702.
60. Alaniz C, Pogue JM, (2012) Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR Trial. Ann Pharmacother 46: 1432-1435.
61. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, et al. (2012) Linezolid in Methicillin- Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clin Infect Dis 54: 621-629.
62. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, et al. (2010) Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 199: 804-816.
63. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, et al. (2009) Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48: 203-212.
64. Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, et al. (2008) Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134: 1200-1207.
65. Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, et al. (2008) Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 32: 241-249.
66. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, et al. (2007) Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60: 1361-1369.
67. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, et al. (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49: 2260-2266.
68. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, et al. (2004) Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53: 345-355.
69. Wilcox M, Nathwani D, Dryden M, (2004) Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 53: 335-344.
70. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, et al. (2003) Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 22: 677-686.
71. Wunderink RG, Cammarata SK, Oliphant TH, (2003) Kollef MH; Linezolid Nosocomial Pneumonia Study Group (2003) Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25: 980-992.
72. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, et al. (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34: 1481-1490.
73. Rubinstein E, Cammarata S, Oliphant T, (2001) Wunderink R; Linezolid Nosocomial Pneumonia Study Group (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32: 402-412.
74. San Pedro GS, Cammarata SK, Oliphant TH, (2002) Todisco T; Linezolid Community-Acquired Pneumonia Study Group (2002) Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 34: 720-728.
75. Walkey AJ, O'Donnell MR, Wiener RS, (2011) Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139: 1148-1155.
76. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, et al. (2010) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 38: 1802-1808.
77. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH, (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124: 1789-1797.
78. Kiem S, Schentag JJ, (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52: 24-36.
79. Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, et al. (2010) Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 138: 1356-1362.
80. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, et al. (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320.
81. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, et al. (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98.
82. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP, (2008) Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 14: 116-123.